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Abstract
Background: Bupleurum marginatum Wall. ex DC (Apiaceae) is a perennial herb widely used in traditional Chinese
and Kampo medicine for the treatment of various infectious diseases. The biological activities of B. marginatum
have not been fully investigated. This study aims to investigate the antitrypanosomal, antimicrobial and antiviral
activities of methanol (ME) and dichloromethane (DCM) extracts of B. marginatum aerial parts and the ability of
both extracts to inhibit the growth of different cancer cell lines.
Methods: Phytochemical characterization of the extracts was performed by LC-MS profiling. The antitrypanosomal
activity was evaluated using the resazurin method. The antimicrobial activity was assessed using agar diffusion and
microdilution methods, and the minimum inhibitory concentration (MIC) values were determined. The antiviral
activity was determined for 6.25, 12.5, and 50 μg/mL doses using a plaque reduction assay. Cytotoxicity was
investigated in eight cancer cell lines (Caco-2, CCL-81, CCRF-CEM, COS-7, HL-60, MIA PaCa-2, MCF-7, and PANC-1)
using the MTT assay and the caspase 3/7 activity was determined over the range of 62.5–1000 μg/mL.
Results: Phytochemical analyses resulted in the characterization of 15 components, mainly flavonoids and lignans.
The DCM extract showed significant antitrypanosomal activity (IC50: 36.21 μg/mL) and moderate activity against
Streptococcus pyogenes (MIC value: 0.25 mg/mL). At a dose of 12.5 μg/mL, the DCM extract inhibited 73.6% of the
plaque production by hepatitis A virus. CCRF-CEM cells were the most sensitive to both extracts (IC50: 12.5–22.7 μg/mL).
The cytotoxicity was mediated by induction of apoptosis (19-fold increase in the cellular caspase 3/7 level after
treatment with the DCM extract at 1 mg/mL).
Conclusions: ME and DCM extract of B. marginatum showed anti-infective and antiproliferative effects.
Introduction
Plants have been the foundation of traditional medicinal
systems in many countries for hundreds of years to pre-
vent or treat ailments and health disorders. Despite the
tremendous success in manufacturing synthetic, semi-
synthetic therapeutic agents or both, approximately 80%
of the world population still relies on herbal medicines
for their health care [1].
The family Apiaceae comprises more than 3500 spe-
cies, of which 300 are medicinally active and have been
used in folk medicine [2]. Among the Apiaceae genera,
Bupleurum encompasses about 180–190 species [3].
Bupleurum marginatum Wall. ex DC is a perennial herb
of up to 60 cm in height, with oblanceolate leaves and
yellow umbel flowers, and used in Chinese medicine [4].
B. marginatum has been widely used in Europe, China,
Korea, and Japan in the form of herbal teas, either alone
or in combination with other ingredients, for treatment
of the common cold and inflammation [5,6]. In addition,
it is employed to treat hepatitis, cancer, microbial infec-
tions, and fever associated with malaria [7-9].
The secondary metabolites of B. marginatum have been
investigated previously, and various classes of compounds
were identified. Specifically, saikosaponins were found in
small amounts [10], while flavonoid glycosides and agly-
cones such as rutin, narcissin, isoquercetrin, isorhamnetin,
and quercetin were commonly found in the plant [11]. In
addition, lignans such as marginatoxin [11-13] and many
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phytosterols (stigmasterol, α-spinasterol, β-sitosterol, and
daucosterol) have been described from both the aerial and
subterranean parts [6,12].
Our previous work in 2009 [14] investigated the anti-
bacterial, antifungal, antioxidant, anti-inflammatory and
cytotoxic activity of the essential oil from the B. margin-
atum aerial parts. To our knowledge, the biological ac-
tivities of different extracts from B. marginatum have
not been studied in detail.
This study aims to investigate the antitrypanosomal,
antimicrobial and antiviral activities of methanol (ME)
and dichloromethane (DCM) extracts of B. marginatum
aerial parts and the ability of both extracts to inhibit the
growth of different cancer cell lines.
Methods
Plant materials
The aerial parts of B. marginatum were kindly provided
by Prof. Thomas Efferth (University of Mainz, Mainz,
Germany). The identity of the plant was ascertained by
one of the authors (MA) in our laboratory by DNA bar-
coding and confirmed morphologically at the Botanical
Garden, Heidelberg University (Heidelberg, Germany).
Voucher specimens of the plant material were deposited
at the Department of Biology, Institute of Pharmacy and
Molecular Biotechnology, Heidelberg University under
accession number IPMB P7367.
Chemicals
Chemicals were purchased from AppliChem® (Darmstadt,
Germany), Fluka® (Buchs, Switzerland), and Sigma® (Sternheim,
Germany). The solvents used were of analytical grade
unless otherwise mentioned, and were purchased from
Merck® (Darmstadt, Germany), J.T. Backer® (Deventer,
Netherlands), and Theo Seulberger® (Karlsruhe, Germany).
Media and supplements for cell cultures were obtained
from Gibco® (Invitrogen, Karlsruhe, Germany) and Greiner
Labortechnik® (Frickenhausen, Germany).
Preparation of ME and DCM extracts
The ME and DCM extracts were prepared by refluxing
100 g of finely milled, air-dried aerial parts of B. margina-
tum with 1.5 L of methanol or dichloromethane, respect-
ively, for 6 h. The extracts were filtered, dried by passage
over anhydrous sodium sulfate, and evaporated to dryness
under reduced pressure at 40°C in a Büchi rotavapor R-
200 with B-172 Büchi vacuum system (Büchi Labortechnik,
Flawil, Switzerland). The dried extracts were stored at 4°C
in the dark until analysis.
General experimental procedures
LC-MS profiling of the extracts
The LC-ESI-MS system used consisted of a Merck Hitachi®
HPLC system (Hitachi Ltd., Tokyo, Japan) composed of a
binary L-6200A intelligent pump, an ERC-3215α degasser
(ERC Inc., Saitama, Japan), a rheodyne injector with a
20-μl loop, and a LiChroCART RP-18, endcapped (5 μm),
250 × 4 mm i.d. column (Merck, Darmstadt, Germany)
coupled with a Micromass VG Quattro II mass spectro-
meter (Waters, Manchester, United Kingdom). The ESI-
MS system was operated using Waters MassLynx 4.0 soft-
ware as described in our previous work [15]. The mobile
phase was a linear gradient of 100% water (containing 0.5%
formic acid) to 50% acetonitrile at a flow rate of 1 mL/min
over 60 min, followed by a linear gradient to 100% aceto-
nitrile over 10 min. Mass spectrometric detection of pheno-
lics was performed in both the positive and negative ion
modes over the range of 400–1400m/z by N2 as a nebulizer
gas and a source temperature of 120°C. The chromato-
grams were processed by Waters MassLynx® 4.0 software
(Waters Corporation, Milford, MA , USA).
Biological activities
Antitrypanosomal activity
Mature bloodstream forms of Trypanosoma brucei brucei
TC221, the causative agent of Nagana (which can be used
as a model for human sleeping sickness), were grown in
Baltz medium supplemented with 20% inactivated fetal
bovine serum and 1% penicillin-streptomycin. The cells
were incubated in a humidified atmosphere containing
5% CO2 at 37°C.
Trypanocidal activity was determined by resazurin as a
cell proliferation indicator dye as previously described
[16]. The extracts were serially diluted with medium in a
two-fold manner to attain final concentrations in the
range of 250 to 3.9 μg/mL in 96-well Plates. T. b. brucei
was seeded into 96-well plates at a density of 1 × 104
cells/well in 100 μL of medium. The cells were then in-
cubated with various concentrations (3.9–250 μg/ml) of
the test samples for 24 h. Ten microliters of resazurin
was added to each well and incubated for a further 24 h.
The absorbance of the wells was recorded by a Tecan®
plate reader (Männedorf, Switzerland) at dual wavelengths
of 492 and 595 nm, and the IC50 was calculated [17].
Each sample concentration was tested in triplicate, and
the experiments were repeated independently twice. The
maximum concentration of the solvent (DMSO) did not
exceed 1.25% in the medium that contained the highest
concentration of each test sample. Diminazene aceturate
was used as a positive control (IC50: 0.088 μg/mL) [18].
Antimicrobial activity
Microbial strains The antimicrobial activity was evaluated
by standard strains. The Gram-positive bacteria examined
included Bacillus subtilis (ATCC 6051), Staphylococcus
aureus (ATCC 29213), Staphylococcus epidermidis (ATCC
14990), Streptococcus pyogenes (ATCC 12344), Streptococ-
cus agalactiae (ATCC 27956), and Methicillin-Resistant
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Staphylococcus aureus (MRSA; NTCC 10442). The Gram-
negative bacteria Escherichia coli (ATCC 25922) and
Pseudomonas aeruginosa (ATCC 27853) were also in-
cluded, as well as the fungi Candida albicans (ATCC
90028) and Candida glabrata (ATCC MYA 2950). Multi-
resistant clinical isolates from patients, such as MRSA
818014 and MRSA 818081, were also examined. All mi-
croorganisms were supplied by Medical Microbiology
Laboratory, Hygiene Institute, Heidelberg University.
Inocula preparation Prior to the test, bacterial and fun-
gal cultures were prepared as follows. The bacterial cul-
tures were subcultured in Columbia medium with 5%
sheep blood (BD, Heidelberg, Germany) and incubated at
37°C for 24 h, while the fungal cultures were subcultured
in CHROMagar® Candida (BD, Heidelberg, Germany) and
incubated at 25°C for 48 h.
Agar diffusion method Suspensions of microorganisms
were prepared in a saline solution and adjusted with 0.5
McFarland Standard to a final concentration of ap-
proximately 1 × 106 CFU/mL as previously reported [14].
Mueller Hinton agar (Biomerieux, Marcy l’Étoile, France)
was inoculated with the pathogens. Wells with a diameter
of 6 mm were cut out by a Pasteur pipette and loaded with
40 μL of 3.2 mg/mL extracts. DMSO, ampicillin, vanco-
mycin, and nystatin were used as controls. The diameters
of the growth inhibition zones were measured in triplicate
after incubation at 37°C for 24 h (bacteria) or 48 h (fungi).
Determination of minimum inhibitory concentration
(MIC) and minimum microbicidal concentration (MMC)
values The MIC was determined by the broth microdilu-
tion method [19]. Various sample concentrations (0.05–
25 μg/mL) were dissolved in 5% DMSO and placed in a
96-well plate (Greiner Bio-one, Frickenhausen, Germany).
The final count of the microbial suspension in Mueller
Hinton broth (Fluka, Buchs, Switzerland) and Sabouraud
Dextrose broth (Oxoid, Hampshire, UK) was adjusted to
approximately 5 × 105 CFU/mL for bacteria and fungi, re-
spectively. The plates were incubated at 37°C for 24 h
(bacteria) or 48 h (fungi)., The suspension (3 μL) from
each incubated well was spread out on medium and incu-
bated at 37°C for 24 h (bacteria) or 48 h (fungi) to deter-
mine the MMC. The MMC was defined as the lowest
concentration of each extract that completely killed the
microorganisms. Each test was performed in duplicate.
The antibiotics ampicillin, vancomycin, and nystatin were
used as positive controls.
Antiviral activity
Antiviral activity was determined by a plaque reduction
assay [20]. Briefly, a confluent layer of Vero cells (CCL-
81) was obtained by culturing the cells for 24 h in 0.5%
CO2 at 37°C. The cells were inoculated, separately with
herpes simplex virus type-1 (HSV-1), hepatitis A virus
(HAV), or vesicular stomatitis virus (VSV) (1 × 10−1 ‒
1 × 10−7 /ml) and incubated at 37°C for 1 h. The infected
cell cultures (2 × 103 PFU) were washed and overlaid
with DMEM containing three concentrations of each
extract (6.25, 12.5, and 50 ìg/mL) for 1 h at room
temperature. Each concentration was tested in three rep-
licates, and the cultures were overlaid with nutrient aga-
rose (2 ×DMEM/1.8% agarose [v/v]) containing 25 mM
MgCl2. After 72 h of incubation, the cells were fixed with
10% formaldehyde in phosphate-buffer solution (pH 7.3)
for 1 h and stained with 0.5% crystal violet in 20% ethanol.
The plaques were counted, and the percentage of viral in-
hibition was calculated as [1 − fVd/Vc)] × 100, where Vd
and Vc are the numbers of plaques in the presence and ab-
sence of the test samples, respectively. Acyclovir was
employed as a positive control.
Cytotoxicity
Cell cultures
Human MCF-7 (breast cancer), PANC-1 (pancreatic car-
cinoma), MIA PaCa-2 (pancreatic cancer), Caco-2 (colon
cancer), and African green monkey kidney COS-7 (fibro-
blast-like epithelium) and CCL-81 (Vero) cell lines were
maintained in DMEM complete medium (L-glutamine
supplemented with 10% heat-inactivated fetal bovine
serum, 100 U/mL penicillin, and 100 U/mL streptomycin),
with addition of 1 mM sodium pyruvate and 10 mM non-
essential amino acids for culture of Caco-2 cells. Human
CCRF-CEM (leukemia) and HL-60 (myeloid) cells were
maintained in RPMI complete medium. The cells were
maintained at 37°C in a humidified atmosphere containing
5% CO2. All experiments were performed with cells in the
logarithmic growth phase.
Cytotoxicity and cell proliferation assay
Cytotoxicity was determined in triplicate using the MTT
cell viability assay [21]. Exponentially growing cells of each
cell line were seeded in 96-well plates (Greiner Labortech-
nik®, Frickenhausen, Germany) at 2 × 104 cells/well. The
cells were cultured for 24 h, and then incubated with vari-
ous concentrations of the extracts ranging from 1 to
1000 μg/mL at 37°C for 24 h. Subsequently, the cells were
incubated with 0.5 mg/mL MTT for 4 h. The formed for-
mazan crystals were dissolved in 200 μL of DMSO. The
absorbance was detected at 570 nm by a Tecan® Safire II
Reader (Männedorf, Switzerland). The cell viability (per-
centage) of three independent experiments was calculated
as follows:
Cell viability %ð Þ ¼ OD of treated cellsð Þ =
OD of control cellsð Þ  100%:
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The cytotoxic agent doxorubicin was used as a positive
control.
Apoptosis assay
The Caspase-Glo™ 3/7 Assay (Promega®, Mannheim,
Germany) was used to detect caspase 3/7 activities in
MIA PaCa-2 cells after treatment with each type of
extract (62.5 to 1000 μg/mL). This test provides a prolu-
minescent caspase 3/7 substrate, which contains the cas-
pase 3-specific tetrapeptide sequence DEVD in a reagent
mix, and is optimized for cell lysis and determination of
caspase activities. Cells cultured in DMEM were seeded
in 96-well plates and treated with the extracts (62.5 μg
to 1 mg). Subsequently, 100 μL of caspase 3/7 reagent
was added to the wells after 6 or 24 h of treatment,
mixed, and incubated at room temperature for 30 min
[22]. The luminescence was measured by a Mithras LB
940 instrument (Berthold Technologies, Bad Wildbad,
Germany). Cellular apoptosis was expressed as the fold
change relative to the untreated control in three inde-
pendent experiments.
Data analysis
All biological experiments were repeated at least three
times. Data were presented as the mean ± standard devi-
ation (SD). The IC50 was determined as the drug con-
centration that resulted in a 50% reduction in cell
viability or inhibition of biological activity. The IC50
values were calculated by a four parameter logistic curve
(SigmaPlot® 11.0, Systat Software Inc., San Jose CA,
USA). The significance of differences in data between
the groups was determined by one-way analysis of
variance followed by the Tukey test for equality of va-
riances using SPSS® 11.0 (SPSS Inc., Chicago, USA).
Differences were considered statistically significant at
P < 0.05.
Results and discussion
HPLC profiling and chemical compositions of the extracts
The chromatographic profiles were established by HPLC/
MS (Figure 1). The ME extract (Figure 1A) revealed the
presence of high contents of flavonoids, and to lesser ex-
tents lignans, sterols, and triterpenoid saponins, as previ-
ously reported by the authors [11]. The DCM extract
(Figure 1B) showed a similar pattern of secondary metab-
olites with higher yields of lignans and terpenoids com-
pared with those detected in the ME extract. These results
are in accordance with our previously detected terpenoids
in the n-hexane extract [14].
In the B. marginatum ME and DCM extracts, the fol-
lowing compounds (Figure 2) were identified unequivo-
cally: quercetin and its glycosides rutin and isoquercetrin;
isorhamnetin and its glycoside narcissin; (3,4-dimethoxy-
benzyl)-2-(3,4-methylenedioxybenzyl) butyrolactone; and
marginatoxin. In addition, sterols such as β-sitosterol and
α-spinasterol and their glucosides, daucosterol, stigmas-
terol, 7-stigmasten-3-ol, 7-stigmast-7,25-dien-3-ol, and
hexadecanol were either isolated or identified from the
different extracts.
Activity against T. b. brucei
The trypanocidal activities of both extracts were illus-
trated in Figure 3. The ME and DCM extracts showed
moderate activities with IC50 values of 104.80 ± 5.11 (P =
0.0027) and 36.21 ± 2.68 (P = 0.0014) μg/mL, respectively.
The selectivity indexes of the two extracts were calculated
as 2.3 and 2.9, respectively, indicating low selectivity
against trypanosomes compared with their cytotoxicity to-
ward HL-60 cells.
Based on previous work [23,24], many flavonoid agly-
cones exhibitantitrypanosomal activity in both in vitro and
in vivo models. However, the activity of most flavonoids
against T. b. brucei and the selectivity of these compounds
were related to the presence of a free phenolic OH group
in position 6 which can dissociate to a phenolate ion
under physiological conditions [23]. Thus, it is probable
that the activity of the extracts could be related to the
presence of several flavonoids that could interact together
in synergistic or even additive manners [25].
To our knowledge, few studies have addressed the
antitrypanosomal activity of lignans [26]. However, two
closely structurally related lignans, justicidin B and pis-
catorin, which were isolated from the aerial parts of
Phyllanthus piscatorum Kunth (Euphorbiaceae), exhi-
bited strong activity against the bloodstream forms of
Trypanosoma brucei rhodesiense with IC50 values of 0.55
and 6.1 μM, respectively [27].
Antimicrobial activity
The antimicrobial activity of the ME and DCM extracts
was assessed by the agar diffusion and microdilution
methods, and the MIC and MMC values were determined
(Tables 1 and 2). In general, both extracts showed growth
inhibition of standard Gram-positive and Gram-negative
bacteria in the diffusion assay. However, no inhibition
zones could be detected for the two fungi and the resistant
pathogenic isolates.
All of the tested Gram-positive bacteria were suscep-
tible to the ME and DCM extracts with MIC values ran-
ging from 0.25 to 4 mg/mL. S. agalactiae and B. subtilis
were sensitive to both extracts with similar MIC values
of 0.5 mg/mL. S. pyogenes was the most susceptible to
the DCM extract with an MIC value of 0.25 mg/mL.
The Gram-negative pathogens and fungi were less sensi-
tive, and their MIC values were ≥ 2 mg/mL. The two ex-
tracts did not differ significantly in their antimicrobial
actions for all of the susceptible microorganisms. However,
they were significantly different from both ampicillin and
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Figure 1 HPLC-MS profiling of the ME (A) and DCM (B) extracts from the aerial part of B. marginatum. 1: rutin; 2: narcissin; 3: isoquercitrin;
4: quercetin; 5: isorhamnetin; 6: lignan 2; 7: marginatoxin.
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vancomycin as seen from the difference in inhibition zones
in Table 1.
Although it was expected that the ME extract of
B. marginatum would possess superior activity com-
pared with the DCM extract based on the richness and di-
versity of secondary metabolites, our findings did not
reveal a significant difference. The expected higher activity
of the ME extract was related to the presence of saikosa-
ponins, which function as detergents and mostly exist in
their mono-desmosidic forms [28]. These compounds can
intercalate via their lipophilic moiety with the lipophilic
membrane bilayer of the pathogens after forming a com-
plex with cholesterol, while the hydrophilic sugar part re-
mains outside of the cell and interacts with glycoproteins
or glycolipids [28]. A loss of the membrane integrity
Figure 3 Dose-dependent growth inhibition of T. b. brucei
(resazurin assay).
Figure 2 Structures of the isolated compounds from the aerial part of B. marginatum.
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Table 2 Minimum inhibitory concentrations (MICs) and minimum microbicidal concentrations (MMCs) of the B. marginatum
extracts against different pathogens determined by the broth microdilution method
Microorganisms CH3OH extract
mg/mL
CH2Cl2 extract
mg/mL
Ampicillin
μg/mL
Vancomycin
μg/mL
Nystatin
μg/mL
MIC MMC MIC MMC MIC MMC MIC MMC MIC MMC
Gram positive
MRSA 818014 4 > 4 4 > 4 6.2 6.2 0.8 0.8 NT NT
MRSA 818081 4 > 4 4 > 4 6.2 50 0.8 0.8 NT NT
MRSA NCTC 10442 4 > 4 4 > 4 6.2 12.5 0.8 1.6 NT NT
Staphylococcus aureus ATCC 29213 4 > 4 4 > 4 0.4 3.1 0.4 0.8 NT NT
Staphylococcus epidermidis ATCC 14990 2 > 4 2 > 4 0.4 0.8 0.8 1.6 NT NT
Streptococcus pyogenes ATCC 12344 0.5 4 0.25 0.75 0.1 0.1 0.1 0.2 NT NT
Streptococcus agalactiae ATCC 27956 0.5 4 0.5 4 0.1 0.2 0.4 0.4 NT NT
Bacillus subtilis ATCC 6051 0.5 2 0.5 1 0.1 0.8 0.2 0.8 NT NT
Gram negative
Pseudomonas aeruginosa ATCC 27853 4 > 4 4 > 4 NI NI NI NI NT NT
Escherichia coli ATCC 25922 2 4 4 > 4 6.2 12.5 NI NI NT NT
Fungi
Candida albicans ATCC 90028 NI NT NI NT NT NT NT NT 1.6 1.6
Candida glabrata ATCC MYA 2950 NI NT NI NT NT NT NT NT 1.6 1.6
NI: no inhibition; NT: not tested.
Table 1 Mean inhibition zones of the B. marginatum extracts against different pathogens determined by the agar
diffusion method
Microorganisms Diameter of inhibition zone (mm)
CH3OH extract
640 μg/well
CH2Cl2 extract
640 μg/well
Ampicillin
10 μg/well
Vancomycin
10 μg/well
Nystatin
10 μg/well
Gram positive
MRSA 818014 NI NI 5.3 ± 0.3 10.3 ± 0.7 NT
MRSA 818081 NI NI 7.2 ± 0.0 10.6 ± 1.3 NT
MRSA NCTC 10442 NI NI NI 10.0 ± 0.2 NT
Staphylococcus aureus ATCC 29213 4.3 ± 0.7 (P*1,2 = 0.001, 0.008) 5.1 ± 1.4 (P1,2 = 0.001, 0.008) 24.0 ± 1.5 10.7 ± 1.6 NT
Staphylococcus epidermidis ATCC 14990 4.3 ± 2.5 (P*1,2 = 0.016, 0.027) 5.6 ± 1.3 (P1,2 = 0.021, 0.019) 12.2 ± 1.7 10.0 ± 0.5 NT
Streptococcus pyogenes ATCC 12344 5.7 ± 1.6 (P*1,2 = 0.006, 0.021) 7.2 ± 2.1 (P1,2 = 0.011, 0.017) 25.0 ± 1.2 15.3 ± 1.6 NT
Streptococcus agalactiae ATCC 27956 5.2 ± 1.1 (P*1,2 = 0.024, 0.021) 5.2 ± 1.5 (P1,2 = 0.023, 0.021) 17.1 ± 1.5 12.0 ± 1.7 NT
Bacillus subtilis ATCC 6051 NI 4.2 ± 2.1 (P1,2 = 0.012, 0.038) 12.7 ± 0.5 8.7 ± 1.2 NT
Gram negative
Pseudomonas aeruginosa ATCC 27853 4.1 ± 0.0 5.3 ± 1.3 NI NI NT
Escherichia coli ATCC 25922 4.3 ± 0.2 NI 5.4 ± 1.2 NI NT
Fungi
Candida albicans ATCC 90028 NI NI NT NT 10.0 ± 1.2
Candida glabrata ATCC MYA 2950 NI NI NT NT 12.1 ± 1.2
Data are presented as means ± SD (n = 3).
NI: no inhibition zone; NT: not tested.
P1,2: Significant differences relative to ampicillin and vancomycin, respectively.
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allows other highly polar flavonoid glycosides to penetrate
the pathogen and exert their effects. On this basis, the
antimicrobial activity is likely to be influenced by the
synergistic and additive effects of all components [28].
Antiviral activity
The ME and DCM extracts showed promising antiviral acti-
vity at a dose of 50 μg/mL. HAV was the most sensitive, show-
ing 76.6% and 81.4% inhibition of viral replication with the
ME and DCM extracts, respectively (Table 3). The antiviral ac-
tivity of the different Bupleurum species have been related to
the contents of saikosaponins, which exert powerful and se-
lective antiviral activity [29-31]. However, the DCM extract
with a low steroid content showed a higher activity than the
ME extract against the three viruses, which might be attributed
to its high contents of lignans and flavonoid aglycones.
Several modes of cytotoxic and antiviral activity were
associated with lignans, including tubulin binding, re-
verse transcriptase, and topoisomerase inhibition [32,33].
However, the most relevant mechanism associated with
lignans involved binding to tubulin, disruption of the
cellular cytoskeleton and spindle apparatus of the in-
fected host cells, and interfering with some critical viral pro-
cesses [32]. Marginatoxin, isolated from a B. marginatum
extract, showed high structural similarity with podophyl-
lotoxin, which was previously reported to show potent ac-
tivity against HSV-1, measles virus, VSV, and many other
viruses [34-36].
In addition, flavonoids constitute the largest group of
secondary metabolites with antiviral activity in the entire
plant kingdom. The several phenolic groups in the fla-
vonoid skeleton, which can dissociate into phenolate
ions and form hydrogen and ionic bonds with amino
acid residues of proteins, facilitates the antiviral activity
by inhibiting viral polymerase activity and binding with
viral nucleic acid or viral capsid proteins, leading to a re-
duction in viral replication [37,38]. Most flavonoids, in-
cluding quercetin and rutin, show promising activity
against HSV-I, HIV-1, HIV-2, poliovirus type 1, parainflu-
enza virus type 3, and respiratory syncytial virus [39-41].
Table 4 Cytotoxicities of the B. marginatum extracts (IC50 values; μg/ml) after 24 h of incubation
Cell lines Methanol extract (μg/mL) Dichloromethane extract (μg/mL) P1 value
Caco-2 108.44 ± 11.43 (P* = 0.012) 56.81 ± 6.30 (P* = 0.009) 0.0011
CCRF-CEM 22.75 ± 2.76 (P* = 0.014) 12.54 ± 1.87 (P* = 0.004) 0.0335
CCL-81 307.51 ± 13.76 (P* = 0.007) 72.81 ± 6.15 (P* = 0.013) 0.0016
COS-7 576.0 ± 11.65 (P* = 0.009) 67.40 ± 2.76 (P* = 0.021) 0.0019
HL-60 100.88 ± 4.02 (P* = 0.021) 35.07 ± 2.28 (p* = 0.007) 0.0026
MIA PaCa-2 22.51 ± 2.98 (P* = 0.023) 14.98 ± 1.09 (P* = 0.018) 0.0388
MCF-7 91.18 ± 8.99 (P* = 0.011) 51.00 ± 5.20 (P* = 0.041) 0.0279
PANC-1 34.81 ± 3.01 (P* = 0.031) 27.62 ± 2.96 (P* = 0.022) 0.0281
Data are presented as means ± SD (n = 3).
P*: Significant difference relative to doxorubicin.
P1: Significant difference relative to each other.
Table 3 Effects of the B. marginatum extracts on viral replication using direct plaque reduction assays
% inhibition in viral replication
HSV-1 HAV VSV
CH3OH extract
6.25 μg/mL 21.75 ± 1.18 33.71 ± 1.82 12.87 ± 1.88
12.50 μg/mL 56.44 ± 1.60 65.01 ± 2.12 41.37 ± 2.16
50.00 μg/mL 66.26 ± 2.72 (P* = 0.0011)a 76.56 ± 4.29 (P* = 0.025)b 56.59 ± 2.03 (P* = 0.0024)c
CH2Cl2 extract
6.25 μg/mL 29.45 ± 1.23 42.51 ± 2.21 39.27 ± 1.95
12.50 μg/mL 59.53 ± 3.41 73.67 ± 3.03 69.55 ± 3.16
50.00 μg/mL 73.91 ± 4.13 (P* = 0.0017)a 81.42 ± 6.15 (P* = 0.019)b 79.96 ± 4.51 (P* = 0.0009)c
Data are presented as means ± SD (n = 3).
HSV-1: herpes simplex virus type-1; HAV: hepatitis A virus; VSV: vesicular stomatitis virus.
P*: Significant difference relative to acyclovir.
aSignificant difference at P = 0.048.
bSignificant different at P = 0.037.
cSignificant difference at P = 0.001.
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Cytotoxicity and apoptosis
The cytotoxicity of the ME and DCM extracts was eval-
uated by eight different human cancer cell lines, Caco-2,
CCL-81, CCRF-CEM, COS-7, HL-60, MCF-7, MIA
PaCa-2, and PANC-1, after 24 h of incubation. The IC50
values are shown in Table 4. The cytotoxicity of the ME
extract ranged from 22.5 to 576.0 μg/mL, while the
DCM extract was more cytotoxic and had IC50 values
ranging from 12.5 to 72.8 μg/mL. Both CCRF-CEM and
MIA PaCa-2 cells were highly sensitive to both extracts,
while the green monkey cells were the most resistant cell
lines. Caspase 3/7 activity was used to measure the abil-
ity of the extracts to initiate the apoptotic cascade. Both
extracts activated caspase 3/7. The increase was most
apparent with the DCM extract, for which a 1 mg/mL
dose produced 19-fold stimulation (Figure 4). The tested
extracts showed higher selectivity for cancer cells when
compared with normal hepatocytes. The ME extract had
no cytotoxic activity against normal human cells over
the range of 1–1000 mg/mL (unpublished data).
Several other Bupleurum species showed similar cyto-
toxicity against different cell lines [42-44]. The mechanism
of this cytotoxicity was attributed to the saikosaponin
content, especially the saponins with an epoxy bridge
[42]. Cytotoxicity is mainly mediated through cell cycle
arrest in the G2/M phase or inhibition of tubulin poly-
merization [45]. In addition, induction of apoptosis via
the activation of kinases 1/2 and several caspases might
be involved [43-45].
Furthermore, quercetin and lignans contributed to the
overall cytotoxicity of both extracts. Quercetin blocks
signal transduction pathways by inhibiting many kinases,
including protein tyrosine kinases and serine/threonine
protein kinases, resulting in arrest of the cell cycle at the
late G1 phase [46] with a proapoptotic activity through ac-
tivation of KRAS and PI3K [47]. Most lignans, especially
those with a structural similarity to podophyllotoxin are
known cytotoxic agents [48]. These agents bind to tubulin,
leading to inhibition of microtubule formation, and inhibit
DNA topoisomerase, thus blocking cell division in the
late G2 [49].
The low cytotoxicity of both extracts toward Caco-2
cells compared with the other tested cancer cell lines
may arise through the overexpression of multidrug-
resistance genes, such as MDR1 and MRP1, in this cell
line [50,51]. These ATP-dependent efflux transporters
facilitated the efflux of xenobiotics from Caco-2 cells,
thereby reducing th\e internal concentration of cytotoxic
drugs and thus their activity [52].
In this work, we investigated the antimicrobial activity
of Bupleurum extracts, especially against Gram-positive
bacteria such as Streptococcus and Bacillus. Moreover,
the antitrypanosomal and antiviral activities of the DCM
extract were explored against three different viruses.
Further studies of the isolated compounds present in the
extracts, particularly lignans, which might serve as lead
compounds and could be modified to increase their se-
lectivity were required. However, clinical reports should
be collected from patients using these Bupleurum prepa-
rations to monitor the efficacy, as well as any side effects
or herbal drug interactions.
Conclusions
In this study, ME and DCM extracts of B. marginatum
showed anti-infective and antiproliferative effects.
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